Non-small cell lung cancer Archives

September 17, 2024

Categories

Active Clinical Trials

Now Enrolling: PrE1702 Real-World Data Study for Patients with EGFR-Mutated Non-Small Cell Lung Cancer Not Enrolled in Clinical Trials

This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial

March 7, 2024

Categories

Active Clinical Trials

Now Enrolling: EA5221/ACHIEVE for Older Adults With Advanced Non-Small Cell Lung Cancer

ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy

March 7, 2024

March 7, 2024

Categories

Active Clinical Trials

Trial Spotlight: Helena Yu Gives an Update on the EA5182 Trial for EGFR-Mutant Non-Small Cell Lung Cancer

This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer

December 19, 2023

Categories

Active Clinical Trials

Trial Spotlight: A Closer Look at ECOG-ACRIN’s Lung Cancer Studies

These four lung cancer treatment trials are all open and enrolling patients

December 22, 2021

Categories

Active Clinical Trials

Trial Spotlight: Helena Yu on the EA5182 Trial for Metastatic, EGFR-Mutant Non-Small Cell Lung Cancer

This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy

May 28, 2021

Categories

People

ECOG-ACRIN Names Vanderbilt University’s Christine Lovly as Its 2021 Young Investigator of the Year

Dr. Lovly is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a highly prestigious recognition of research excellence